Systemic shift in liquid biopsy diagnostics: single-vesicle profiling reveals structural barriers to equitable healthcare adoption
Original framing: “Single-vesicle profiling could push liquid biopsies toward everyday clinical use” — Phys.org
Single-vesicle profiling offers unprecedented resolution in detecting early-stage diseases by analyzing individual extracellular vesicles (EVs), but its clinical utility is constrained by reproducibility issues and lack of standardized protocols. The scientific literature highlights that 80% of EV research is concentrated in 5 countries, creating a geographic bias that skews biomarker discovery toward diseases prevalent in high-income settings. Additionally, the focus on protein/RNA cargo ignores the role of lipids and metabolites, which may hold equal diagnostic value but are understudied due to methodological limitations.
The single-vesicle profiling narrative exemplifies how biomedical innovation is co-opted by capitalist and colonial logics, where a tool promising to democratize diagnostics risks deepening global health inequities.
Historically, diagnostic technologies have been weaponized against marginalized communities—from the Tuskegee experiments to the exploitation of Henrietta Lacks’ cells—yet the current framing ignores these precedents, instead celebrating a 'breakthrough' that serves elite patients first. Indigenous knowledge systems, which have long used fluid-based diagnostics, offer a corrective to the reductionist paradigm of Western medicine, but their erasure reflects a broader epistemicide in global health. The solution lies not in technological fixes alone but in dismantling patent regimes, reallocating R&D funding toward public health, and centering community governance—transforming liquid biopsies from a commodity into a commons. Without these systemic shifts, single-vesicle profiling will remain a trickster’s gift: a messenger of healing that also carries the seeds of further exclusion.